尿路1生器腫瘍に対するUFTの臨床成績

Abstract

UFTを腎細胞癌7例, 膀胱癌5例, 前立腺癌4例に投与した.1)抗腫瘍効果は, complete response (CR) 2例, partial response (PR) 2例, NC 12例で, PDはみとめず, 有効率は16例中4例であった.2)腎細胞癌では7例中CR 1例, PR 1例, 膀胱癌では5例中CR 1例, PR 1例であったが, 前立腺癌4例はすべてNCであった.3)副作用は, 600 mg/日投与6例中3例に, それぞれ食欲不振, 嘔気と嘔吐, 口内炎をみたが, 300 mg/日投与例に消化器症状はみなかった.4)骨髄機能の抑制や, 肝, 腎機能障害はみなかった

Clinical study of UFT which was a mixture of FT and uracil, was conducted on 16 patients with urogenital malignancies. Seven patients had renal cell carcinoma, 5 patients had bladder cancer and 4 patients had prostatic cancer. UFT was continuously administrated at doses of 300 mg or 600 mg per day. One of the patients with renal cell carcinoma and 1 of the patients with bladder cancer showed a complete response, and 1 patient with each cancer showed a partial response, but none of the 4 patients with prostatic cancer responded. In total, complete or partial responses were obtained in 4 of the 16 patients, given an effective rate of 25.0%. Concerning side effects, 3 of the 16 patients complained of anorexia, nausea and vomiting, and stomatitis, but no hepatic or renal disorders, or marrow depression was observed.